The 'top dog' of industrial robots: net profit surges over 21-fold in the first half!

On the evening of July 14, Nanjing Estun Automation Co., Ltd. (002747.SZ, hereinafter referred to as “Estun”) released its preliminary 2026 semi-annual performance forecast. According to the announcement, the company expects its net profit attributable to shareholders of the listed company for the first half of 2026 to range between RMB 150 million and RMB 180 million—representing a dramatic year-on-year increase of 2,144.74% to 2,593.68%, compared with RMB 6.6823 million in the same period last year. Non-GAAP net profit (excluding non-recurring gains and losses) is expected to be between RMB 60 million and RMB 75 million, reversing from a loss of RMB 17.6028 million in the same period last year—achieving profitability and registering a year-on-year growth of 440.85% to 526.07%. Basic earnings per share are projected at RMB 0.17 to RMB 0.21, up from RMB 0.01 in the same period last year. According to the announcement, the substantial growth in performance stems primarily from three factors: First, continuous optimization of product mix. During the reporting period, the company focused on high-value-added products and high-quality orders, while strengthening price management, optimizing supply chains and R&D design, and implementing lean manufacturing—measures that collectively drove a significant improvement in gross margin year-on-year.

Moderna Q1 2026 Earnings: Net Loss of $1.3 Billion, Yet 2026 Goals Are Clear—10% Revenue Growth Target

On May 1, 2026, Moderna announced its financial results for the first quarter of 2026 and provided an update on business progress. Key Highlights: • First-quarter revenue totaled $389 million, approximately 80% of which came from international markets. • GAAP net loss for the quarter was $1.3 billion, with GAAP earnings per share of -$3.40—$900 million of which consisted of non-recurring litigation settlement expenses. • The company reaffirmed its 2026 guidance: revenue growth of up to 10% and GAAP operating expense reductions—excluding non-recurring litigation settlement expenses. • Its infectious disease portfolio achieved key regulatory milestones in the EU, including approvals for mNEXSPIKE and mCOMBRIAX (Moderna’s flu + COVID-19 combination vaccine). • Initiated a Phase III clinical trial evaluating intismeran autogene as monotherapy and in combination with KEYTRUDA® QLEX for high-risk Stage I non-small cell lung cancer (NSCLC). Stéphane Bancel, Chief Executive Officer of Moderna, stated: “The Moderna team got off to a strong start this year, building on actions taken in 2025 to deliver significant revenue growth and substantial cost reductions. We secured two European product approvals—including mCOMBRIAX, the world’s first flu + COVID-19 combination vaccine. Additionally, we launched a new pivotal trial for intismeran—the first Phase III monotherapy study targeting high-risk Stage I NSCLC patients. Building on the robust momentum of Q1, we are pleased to be back on a trajectory of sales growth in 2026 and anticipate multiple new global approvals—including our seasonal flu vaccine, which will become Moderna’s fifth approved product. We also look forward to important pivotal trial readouts this year for norovirus, intismeran in melanoma, and the propionic acidemia program.” Commercial Updates In Q1, Moderna advanced its multi-year revenue growth strategy through strategic partnerships and key regulatory approvals. In the UK, the company completed its first product deliveries under a long-term strategic partnership agreement. Moderna also received European regulatory approvals for mNEXSPIKE, the flu + COVID-19 combination vaccine mCOMBRIAX, and mRESVIA—approved for all adults aged 18 years and older. Q1 2026 Financial Results Revenue: Total revenue for Q1 2026 was $389 million, an increase of $281 million year-on-year. U.S. market revenue amounted to $78 million, while international market revenue reached $311 million. Growth in net product sales was primarily driven by increased COVID-19 vaccine volumes, fueled by deliveries under long-term strategic partnerships with government agencies—predominantly in international markets. Cost of Sales: Cost of sales for Q1 2026 totaled $955 million, including $895 million in third-party royalty fees and $38 million in inventory write-downs. Compared with the same period in 2025, cost of sales increased by $865 million—primarily due to $878 million in litigation settlement-related expenses recognized within third-party royalty fees during Q1 2026.

Ecovyst Inc. Reports Q2 2026 Earnings Beat

Aug 5, 2026

Ecovyst Inc. reported Q2 2026 earnings with an EPS of $0.21, exceeding estimates by $0.02. Revenue hit $250 million, reflecting a 24.94% year-over-year increase.

Seeking Alpha

2026-07-25

Ecovyst Inc (ECVT) Q4 2022 Earnings Report

2026-08-05

Ecovyst Inc. Reports Q2 2026 Earnings Beat

2026-08-05

Ecovyst Releases Q2 2026 Financial Results

2026-08-07

Ecovyst (NYSE:ECVT) Posts Earnings Results, Beats Expectations By $0.02 EPS

Ecovyst Inc. Reports Q2 2026 Earnings Beat

FAQ